On November 4, 2025, the company issued a press release announcing its unaudited results of operations for the 3 and 9 months ended September 30, 2025 and its unaudited financial position as of September 30.

1. 01

   On November 4, 2025, the company issued a press release announcing its unaudited results of operations for the 3 and 9 months ended September 30, 2025 and its unaudited financial position as of September 30.

2. 02

   The company said its press release included non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and sub-components of non-GAAP operating expenses such as non-GAAP cost of sales, non-GAAP research and development expenses and non-GAAP selling, general and administrative expenses, along with reconciliations to the most directly comparable GAAP financial measures.

3. 03

   The company said it excludes from GAAP financial measures acquisition-related expenses, net charges from restructuring and cost savings initiatives, and other items including gains and losses on investments in equity securities and certain items associated with legal proceedings when calculating non-GAAP financial measures.

4. 04

   Amgen said it computes Free Cash Flow by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP, and views FCF as a further measure of the company's liquidity.

Analysis scope · Filing body only (exhibits excluded)We analyzed the filing body only. The exhibits exceeded the length limit and were excluded, so figures, financial statements and presentation materials in them were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.